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Abstract 
Solute carrier transporters, previously thought to perform roles in the transport of ions and various 
nutrients are now assigned broader functions. These transporters have recently been shown to permit 
entry of therapeutic drugs into cells. There is growing interest to understand the broad spectrum of drugs 
and chemical compounds that are recognized by these transporters such that specific ligands can be used 
as therapeutics to target definite physiological pathways. To facilitate this investigation, simpler and cost 
effective model systems are needed, one of such is the live whole model animal Caenorhabditis elegans (C. 
elegans) that offers a multitude of advantages. In general, studies with C. elegans are feasible due to the 
simplicity of the readouts that include lifespan, brood size, germ cell death, and visualization by 
epifluorescent microscopy, which can be set up in any laboratory. In C. elegans, two solute carrier 
transporters, the organic cation transporters OCT-1 and its paralogue OCT-2 have been partially 
characterized. OCT-1 mutants display a significantly reduced lifespan and brood size, as well as exhibiting 
an increased susceptibility towards oxidative stress and a subset of DNA damaging agents. These multiple 
phenotypes are directly linked to OCT-1 depletion causing upregulation of OCT-2, as RNAi-mediated 
downregulation of OCT-2 rescues the oct-1 mutant phenotypes. Thus, in C. elegans OCT-1 exerts control 
onto OCT-2, and this latter transporter plays a predominant role in the uptake of various ligands. We first 
showed that OCT-2 can efficiently mediate uptake of the widely used anticancer drug doxorubicin into the 
animals, but prevented uptake upon its downregulation. Additional ligands of OCT-2 including cisplatin and 
camptothecin were revealed by ligand-docking prediction studies. These analyses generated docking scores 
indicating that OCT-2 can make robust contact with a number of therapeutics and anticancer drugs, as well 
as chemical compounds that possess the ability to target specific physiological pathways. Several of the 
compounds displaying high docking scores with OCT-2 were validated and indeed found to be substrates 
that OCT-2 transported into the animals. This review provides an insight how the transporters OCT-1 and 
OCT-2 of a simple model organism C. elegans can be exploited to report on the cytotoxicities and 
genotoxicities of therapeutic agents, as well as trace amounts of undocumented toxic compounds with 
neoplastic potentials that are present in the environment. 
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Introduction 
The mainstay chemotherapeutics such as anthracyclines, cisplatin and radiomimetic drugs are often 
used to eliminate cancer cells and reduce the burden of tumors by inflicting damages to the genome [1-3]. 
These genotoxic agents are administered to cancer patients in combination, and in some cases with small 
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molecule inhibitors to block DNA repair pathways with the aim of sensitizing cancer cells towards the 
chemotherapeutic regimens [4-8]. Although these molecules are hydrophilic in nature, it was commonly 
accepted that they diffuse into cells. This notion has been challenged as most chemotherapeutics are 
charged molecules and structurally unrelated, and thus cannot easily cross the plasma membrane barrier. 
Moreover, a single chemotherapeutic agent does not show the same genotoxicity when given to different 
cell types, as would be expected in the case of simple drug diffusion. In fact, there is now growing evidence 
that these charged anticancer drugs depend on facilitated transport mechanisms to enter cells in order to 
effectively reach the target sites.  
In human cells, there are over 450 solute carrier transporters, which are believed to facilitate the 
uptake of nutrients and ions. However, these transporters also perform functions that are distinct as 
defects in 30 % of the transporters are linked to diseases that may be related to imbalances in the uptake 
of nutrients and ions at specific locations. For example, mutations in SLC22A4 lead to Crohn disease, which 
affects the gastrointestinal tract and mutations in SLC12A3 lead to Gitelman’s syndrome characterized by 
low blood pressure [9, 10]. Besides the uptake of nutrients and ions, some of these transporters are 
actively involved in the influx of drugs for treating various illnesses. At least 12 of the transporters are 
specifically involved in the transport of drugs approved by the Food and Drug Administration (FDA), e.g, 
SLC6A3 transports methylphenidate used for treating psychiatric disorders [11]. In addition, a few of the 
solute carriers have been shown to mediate uptake of anticancer drugs. For example, the SLC35F2 
transporter is completely responsible for the uptake into human tumour cells of the anticancer drug 
YM155, which is currently in clinical evaluation [12]. Another recent study established that the organic 
cation transporter SLC22A2 (OCT2) is required for oxaliplatin uptake into renal cells and that 
downregulation of OCT2 is a cause for oxaliplatin resistance in renal cell carcinoma [13]. However, these 
resistant renal cell carcinoma can be sensitized to oxaliplatin upon restoring OCT2 expression [13]. In a 
final example, the functional level of another member of the organic cation transporter family, SLC22A1 
(OCT1), was shown to be a critical marker for the responses of chronic-phase chronic myeloid leukemia 
towards the tyrosine kinase inhibitor imatinib [14]. Patients with low activity levels of OCT1 respond poorly 
to imatinib and exhibit lower overall survival as compared to those with high levels of OCT1 [14]. This same 
transporter was also shown to transport the diabetes drug metformin, which decreases production of 
hepatic glucose, thus underscoring the possibility that many of the transporters may likely recognize 
multiple substrates [15]. These foregoing studies raise the possibility that although the transporters may 
have evolved to mediate uptake of common nutrients and ions, they have the ability to recognize distinct 
ligands. While it is difficult to determine the ligands for each transporter, it is anticipated that with a given 
substrate the transporter can be identified through biochemical and genetic analyses.  
Since anthracyclines are widely used chemotherapeutic agents and initially believed to diffuse into cells, 
there has been little interest to determine whether a transporter exists for these drugs. We challenged the 
initial view and used anthracyclines as the ligands to search for a transporter. Below highlights the key 
findings that establish the existence of a human transporter OCT1, which mediates uptake of 
anthracyclines into cells and how this discovery was exploited to uncover similar transporters in the model 
organism Caenorhabditis elegans (C. elegans).  
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Human OCT1 transports anthracyclines 
Anthracyclines such as doxorubicin and daunorubicin act by intercalating with the DNA and blocking the 
function of DNA topoisomerase leading to the accumulation of DNA lesions and subsequent cell death [16]. 
Monitoring anthracyclines entry into cells was made possible as these drugs autofluoresce at 640 nm, 
which provides an important physical property for the development of in vitro assays to quantitatively 
assess the intracellular uptake levels. These in vitro assays monitor drug uptake into the cells as a function 
of time using quantitative approaches such as fluorescence-activated cell sorting (FACS) analysis and 
fluorometry, as well as a semi-quantitative method involving epifluorescence microscopy [17, 18]. Using 
these assays and a panel of cancer cell lines such as the leukemia HL60 and the ovarian TOV222G2 cell 
lines, it was shown that daunorubicin or doxorubicin at 5 µM enters these cells in a time- and a 
concentration-dependent manner and reaching saturation within 60 min [19]. These observations establish 
for the first time that there is an active transport mechanism for anthracyclines into cells, eliminating the 
possibility that diffusion accounts for the major accumulation of the drug into cells [19]. Although earlier 
studies claimed that the active transport mechanism for doxorubicin uptake involved the human SLC22A16 
(hCT2/OCT6) and SLC22A4 (OCTN1) transporters, subsequent findings proved that these were not the 
transporters [18, 20, 21]. However, it was studies from the budding yeast Saccharomyces cerevisiae that 
provided clues to the actual transporter by directly linking anthracycline-mediated uptake to the family of 
OCT transporters. In human cells, there are three OCT homologues OCT1, OCT2 and OCT3 that are 
members of one family of organic cation transporters all of which can transport choline with varying 
affinities. We therefore conducted competition experiments with the human cancer cell lines and 
documented that choline completely blocked the uptake of daunorubicin into the cells when added at 
nearly equimolar amounts [19]. Since OCT1 has a higher affinity for choline than OCT2 and OCT3 and can 
mediate uptake of several different ligands into cells, it is strongly suggested that it could be a suitable 
candidate to explore for a role in anthracycline uptake. The first direct evidence came from silencing OCT1 
expression by shRNA in the ovarian cancer cells TOV222G2, which sharply reduced the OCT1 protein level, 
as revealed by anti-OCT1 antibodies [19]. These OCT1 downregulated cells showed nearly 85 % reduction 
in daunorubicin uptake when compared to the control shRNA that showed no effect [19]. As a corollary 
experiment, overproduction of OCT1 which is localized to the plasma membrane, stimulated daunorubicin 
uptake into the cancer cell lines [19]. Collectively, these studies provide the first convincing evidence that 
OCT1 functional level might be pivotal in determining the effectiveness of treatment with anthracyclines. 
Since anthracyclines are used for treating leukemia as well as several other types of cancers such as 
lymphomas, breast, ovarian, and gastric, it is anticipated that patients who are refractory to anthracycline 
treatment are likely to be defective in the uptake transporter [22-26]. Conversely, patients with induced 
levels or activated OCT1 could be hypersensitive to anthracyclines. 
Because the human OCT1 transporter displays broad substrate specificity, it is imperative to investigate 
whether its function in drug transport can be influenced by the presence of additional drugs, nutrients, and 
or the status of other influx and efflux transporters. As such, it seems logical that a well characterized OCT1 
transporter would be beneficial in choosing the appropriate drug, without competition by other substrates, 
for targeted entry into cells. To rapidly address these issues, it would require a simple live whole model 
system that is readily tenable to genetic modifications and cost effectiveness such as Caenorhabditis 
elegans.  
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C. elegans as a model to facilitate studies on drug uptake transporters  
C. elegans has been chosen as the whole model system as it offers a multitude of advantages over 
mammalian cells to rapidly study many highly conserved biological processes [27]. C. elegans developed 
from eggs to the adult stage within three days spanning four larval stages. Genes can be readily 
downregulated by simply feeding the animals with bacteria expressing double stranded RNA from a 
segment of the coding region of the targeted gene. C. elegans are transparent and facilitate easy 
visualization of germ and somatic cells by microscopy. During the last decade, C. elegans have been 
instrumental in several drug discovery programs that include the search for new antifungals and 
compounds to limit oxidative stress [27, 28], although the contributions of uptake transporters in these 
studies were not considered [29]. Therefore, it is unclear how C. elegans uptake transporters would have 
influenced many of the high-throughput screens performed so far to identify novel small molecules that 
act, for example, as antimicrobials. One possibility is that the yield of bioactive compounds typically 
recovered from these screens, ranging from 0.03 to 1 %, could be substantially higher if there is greater 
influx of the molecules into the animal cells via elevated expression of uptake transporters [27, 30]. Thus, 
defining the function and substrate specificities of uptake transporters in C. elegans will be advantageous 
towards improving the strategies employed to identify novel bioactive molecules. Highlighted below are 
the current progresses regarding the roles of a previously and a recently discovered organic cation 
transporter, OCT-1 and OCT-2, respectively, in C. elegans and how these transporters can be exploited for 
drug testing.  
Uptake transporters in C. elegans 
In comparison to the human genome, there are far fewer organic cation transporters in C. elegans 
following an analysis of the sequence information in the Wormbase. These C. elegans transporters include 
the partially characterized OCT-1 and OCT-2 and at least six other putative transmembrane transporters 
PES-23, OAT-1, SVOP-1, STR-176, HMT-1.1/1.2 and GEM-1. Far less is known about these latter six putative 
transporters and will not be discussed further. The C. elegans OCT-1 and OCT-2 are counterparts of the 
human OCTs and little is still known about their roles and affinities towards distinct ligands. Both OCT-1 
and OCT-2 share 22.56 % identity at the amino acid level, but OCT-2 differs from OCT-1 as it harbours an 
extra 172 amino acid residues at the N-terminal, which has no homology to OCT-1. 
In 1999, OCT-1 was the first uptake transporter identified from C. elegans [31]. The oct-1 gene was 
designed to be expressed in mammalian cells and shown to mediate the transport of the organic cation 
tetraethylammonium, a prototypical substrate used for classifying OCTs, suggesting that OCT-1 has the 
ability to function as an uptake transporter [31]. At the time, no extensive study was done to assess the 
detail substrate specificity of OCT-1 following its expression in human cells. It was much later when the 
next study appeared in 2013 showing that C. elegans deleted for the oct-1 gene exhibited a shortened 
lifespan, as well as an increased susceptibility to oxidative stress [29]. These observations led to the 
proposition that OCT-1 facilitates the import of antioxidants into the animals, which is required to protect 
oct-1 mutant animals from oxidative stress [29]. However, the level of the purported substrate of OCT-1, 
the antioxidant ergothioneine, was not altered in oct-1 mutant animals as compared to the parent [29]. 
Therefore, it seems plausible that an alternative explanation could account for the oct-1 mutant animal 
phenotypes.  
In an attempt to find substrates for OCT-1, we expressed the C. elegans oct-1 gene in another 
heterologous model system, namely the budding yeast Saccharomyces cerevisiae. Since human OCT1 can 
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transport anthracyclines, we first tested these chemotherapeutic drugs. We observed that expression of C. 
elegans OCT-1 can trigger the uptake of doxorubicin into yeast cells. The yeast strain we used was 
defective in Agp2, which has been reported to be a plasma membrane amino acid transporter that also 
performs a regulatory role [32]. Deletion of the AGP2 gene in yeast blocked the expression of several 
target genes including the polyamine transporters Dur3 and Sam3 [18]. Both Dur3 and Sam3 can 
independently transport doxorubicin when overexpressed in yeast cells lacking Agp2 [18]. Therefore, it is 
not clear whether the expression of C. elegans OCT-1 in yeast substituted for the regulatory function of 
Agp2 or directly for the roles of Dur3 and Sam3, since these transporters also mediate uptake of 
doxorubicin [18]. As such, it became necessary to test directly whether OCT-1 might mediate the transport 
of doxorubicin into C. elegans. However, the existence of another related member of the organic cation 
transporter family, namely OCT-2, in C. elegans, suggests that there needs to be a strategy to test the 
contribution of each transporter towards doxorubicin uptake. Prior to our work, there was no function 
assigned to this putative transporter OCT-2 [33]. Moreover, there are no animals in the consortiums, USA 
or Japan, carrying either partial or complete deletion of the oct-2 gene, as in the case of oct-1. Thus, to 
examine whether OCT-1 or OCT-2 or both have roles in the uptake of doxorubicin in C. elegans, we used 
RNA-interference (RNAi) feeding bacteria to generate animals with different genotypes, in particular, 
either downregulated for one or both transporters [33].  
Using this approach, we uncovered several novel findings regarding the OCT-1 and OCT-2 transporters 
in C. elegans. First, unlike the oct-1 null animals, downregulation of oct-2 did not affect the lifespan of the 
animals. Second, perhaps most interesting, the depletion of OCT-2 rescued the shortened lifespan of 
animals already deleted for the oct-1 gene [33]. This striking observation prompted the possibility that 
OCT-1 might influence OCT-2 function, whereby oct-1 downregulation leads to oct-2 upregulation. This 
notion is based on the fact that OCT1 knockout mice manifest upregulation of two related transporter 
genes, OCT2 and OCT3 [34]. And third, quantitative PCR analysis indeed revealed that downregulation of 
oct-1 led to the upregulation of oct-2 expression in several tissues of the animals, while several control 
genes, such as act-1 encoding actin, were unaffected [33]. As such, we proposed that OCT-2 upregulation 
could be responsible for triggering uptake of toxic environmental compounds into the animals and thus 
account for the shortened lifespan displayed by the oct-1 animals.  
There is evidence to support that the upregulation of OCT-2 leads to the import of toxic compounds 
from the environment into the animals. This was documented using a simple reporter animal that harbours 
within its genome the oxidative stress response gene gst-4 encoding glutathione S-transferase 4 fused to 
the Green Fluorescent Protein (GFP) [35, 36]. In C. elegans SKN-1, the counterpart of the mammalian NRF2, 
senses oxidative stress and turn on the expression of gst-4. We used the gst::gfp reporter animals to 
monitor oxidative stress caused by toxic compounds and showed that these animals expressed a basal 
level of GST-4::GFP in the intestine. However, the expression level of the GST-4::GFP was greatly 
stimulated following RNAi downregulation of oct-1 that led to the upregulation of oct-2 [33]. Consistent 
with this observation, downregulation of the oct-2 transporter gene by RNAi lowered the basal levels of 
GST-4::GFP expression in the reporter strain [33]. Thus, oct-2 upregulation, via oct-1 downregulation, 
allows entry of toxic compounds such as prooxidants into C. elegans. These prooxidants increased the 
oxidative stress of the animals that could cause oxidative damages to various macromolecules, such as 
DNA, and leading to the shortened lifespan of the oct-1 null animals.  
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OCT-2 mediates the accumulation of doxorubicin in C. elegans tissues 
Equipped with the new knowledge on the regulation of oct-2 by OCT-1, we checked if these 
transporters possess the ability to drive doxorubicin uptake and accumulation into C. elegans tissues. In 
the design of the experiment, the fluorescent property of doxorubicin, emitting fluorescence at 
wavelengths of λ
ex
470 nm - λ
em
585 nm, became a convenient means to monitor its uptake in situ by 
imaging the pharynx, a very large and visible organ. On the basis of the previous studies in both human and 
yeast cells, we anticipated that C. elegans OCT-1 would act as an uptake transporter and that oct-1 null 
animals would display very little doxorubicin uptake [18, 19]. Unexpectedly, we observed that the C. 
elegans oct-1 null mutant exposed to doxorubicin depicted a markedly stimulated fluorescence intensity of 
the drug in the pharynx, as compared to the parent animals [33]. The simplest explanation for this finding is 
that deletion of the oct-1 gene resulted in the upregulation of oct-2, and it is OCT-2 that is responsible for 
doxorubicin uptake. Indeed, the downregulation of oct-2 via RNAi feeding bacteria of the oct-1 null mutant 
completely blocked the uptake of doxorubicin, clearly indicating that OCT-2 and not OCT-1 has a 
predominant role in the drug uptake [33]. These observations in C. elegans contradict the previously 
reported role for OCT-1 as an uptake transporter [18, 31]. It is possible that in the natural environment 
OCT-1 may be modified to exert a distinct role other than functioning as an uptake transporter or 
alternatively exhibits specificity for an entirely different class of substrates. Based on the present evidence, 
we believe that OCT-2 might be the key transporter that mediates doxorubicin uptake into C. elegans. OCT-
2 also has the ability to recognize and transport other cationic compounds. For example, choline can 
compete for the uptake of doxorubicin entry into C. elegans, suggesting that it is likely a substrate for OCT-
2 [33, 37]. In fact, choline is a substrate for human OCT1 and it impedes the uptake of daunorubicin into 
human cell lines [19]. It is reasonable to propose that any compound that competes for doxorubicin uptake 
into the C. elegans oct-1 null animals is likely a putative substrate for OCT-2, thus providing a foundation to 
develop a screening tool to find therapeutic compounds that are transported by OCT-2. In developing this 
assay further, it is noteworthy that other factors should be considered such as compounds, e.g., spermine 
that could quench the fluorescence of doxorubicin leading to false positives. Nonetheless, the same assay 
can be extended to find compounds that could stimulate doxorubicin uptake revealing activators for OCT-2.  
OCT-1 and OCT-2 play a pivotal role in controlling germ cell death  
In a manner similar to many stem cell systems, C. elegans has a self-renewing germ cell population [38]. 
These germ cells are very sensitive to genotoxic compounds and respond by using conserved DNA repair 
mechanisms to faithfully maintain genomic stability [39]. Germ cells with extensive DNA damage undergo 
apoptosis and cannot form viable embryos, and which can be quantified in vivo by examining for corpses in 
the proximal zone of the gonad arm [38, 40, 41]. These corpses are easily seen by staining with the DNA 
dye acridine orange [38, 40, 41]. Thus, germ cell apoptosis is a suitable in vivo reporter system to 
determine whether natural compounds and those in the growth environment of the animals are genotoxic. 
We took advantage of this reporter system to assess whether OCT-1 and OCT-2 control the extent of germ 
cell death triggered by genotoxic agents, in particular, those compounds that cannot be tracked directly for 
their uptake kinetics due to the absence of a fluorescence signal or the availability of radioactively labeled 
form. In the wild type animals grown under normal conditions, there are typically two to four germ cell 
corpses [42]. However, when oct-1 is downregulated the animals depicted an average of five to eight 
apoptotic cells, perhaps resulting from an increase import of genotoxic prooxidants by the elevated levels 
of the OCT-2 transporter leading to dead embryos [33]. Interestingly, downregulation of oct-2 in the oct-1 
null mutant reduced the germ cell death, and in some animals to undetectable level. It seems that OCT-2 
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possesses the ability to recognize and transport toxic compounds from the growth environment into the 
animals which then induced germ cell death. At least, these toxic compounds can turn on the oxidative 
stress reporter GST-4::GFP, suggesting that they compose of prooxidants with the ability to cause 
genotoxicity in various tissues [33]. In fact, the oct-1 deficient animals produce an elevated level of dead 
embryos, which are believed to be the result of the accumulation of genotoxic DNA lesions under normal 
growth conditions, and therefore account for the reduced lifespan observed in these animals.  
Since doxorubicin acts by damaging the DNA and previously shown to trigger germ cell apoptosis in C. 
elegans [43], then modulating OCT-2 level should determine the extent of doxorubicin-induced germ cell 
death. Indeed, oct-1 deletion animals showed substantial levels of germ cell deaths when treated with 
doxorubicin, as opposed to the wild-type. This phenomenon was greatly diminished following OCT-2 
downregulation in the doxorubicin treated oct-1 null animals. These observations are consistent with the 
model that oct-1 deletion led to OCT-2 upregulation, which then mediates doxorubicin uptake that induces 
germ cell death. Therefore, germ cell death is a genuine reporter for OCT-2 dependent uptake of genotoxic 
agents.  
Potential substrates of OCT-2 
While it is clear that additional substrates will be recognized by OCT-2, it is an arduous task to test each 
potential substrate, for example, by competing for doxorubicin uptake. As such, we undertook an in silico 
approach by first making predictions of the structure of the transporter using the I-TASSER protein 
structure prediction server [44]. The analysis predicted 3D structures not only for OCT-2, but also OCT-1, 
revealing that both possessed the entire 12 transmembrane domain helices and belonging to the solute 
carrier transporter family [33, 45]. The predicted 3D structures of the transporters were then modeled 
with drugs to look for interactions using the BSP-SLIM and COACH algorithms. These programs 
approximate the amino acid residues of the transporters constituting the ligand–protein docking sites and 
thereby resulting in a docking score [46, 47]. A number of drugs were analyzed and these were mostly DNA 
damaging agents including cisplatin and camptothecin and small molecules with the ability to inhibit DNA 
repair such as olaparib and methoxyamine. Of the 19 potential substrates, four resulted with a docking 
score of zero, whereas the other 15 revealed docking scores > 3.5 [33]. Many showed higher docking 
scores with OCT-2 than OCT-1, favoring robust binding to OCT-2 [33]. From the molecules tested, it seems 
that OCT-2 may distinguish specific substrates to be transported into C. elegans tissues by recognizing an 
overall positive charge and perhaps structural features that include aromatic groups. It is noteworthy that 
there are compounds that can damage the DNA and induce apoptotic corpses such as melphalan and 
methoxyamine. However, these agents do not dock onto OCT-2 or OCT-1, and may therefore require 
alternative transporters to enter the animals [33]. It is anticipated that protein-ligand modeling studies 
should reveal novel substrates for these uptake transporters, but these ligands must be experimentally 
validated as described below for the anticancer drug cisplatin and an inhibitor of DNA repair.  
 
OCT-2-dependent transport of cisplatin stimulates germ cell death in C. elegans mutants defective in 
DNA repair 
Cisplatin, a predicted ligand of OCT-2, is a member of the platinum family of anticancer drugs that 
damages the DNA by creating intra- and inter-strand DNA cross-links [48]. These DNA lesions are repaired 
by the nucleotide excision DNA repair pathway, which has the ability to recognize helix distortion followed 
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by incisions on either side of the lesion [49]. Thus, defects in the nucleotide excision repair pathway cause 
hypersensitivity to cisplatin [49]. As cisplatin is not available in labeled forms, but can be monitored by 
liquid chromatography mass spectrometry, the germ cell apoptotic assay provides a remarkable alternative 
reporter for the uptake of the drug [39, 50]. The analysis revealed that cisplatin induced an increase level 
of germ cell death in the wild type animal, and which was further stimulated in the oct-1 null mutants [33]. 
Downregulation of oct-2 in the oct-1 null mutants prevented the cisplatin-induced germ cell death 
indicating that OCT-2 plays a central role in mediating the genotoxic effects of cisplatin [33]. Thus, the 
ligand-docking studies described above serve as a useful prediction platform to screen for OCT-2 
substrates.  
One prediction from these findings is that the elevated uptake of genotoxic agents into animals 
defective in DNA repair should result in lethal phenotypes. There are several mutants in the C. elegans 
consortium carrying defects in the major DNA repair pathways and which are suitable to test whether OCT-
2 upregulation can trigger sensitization of the animals to DNA damage-induced germ cell death. For 
example, the xpa-1 deletion mutant lacking the XPA-1 protein needed for nucleotide excision repair of 
bulky DNA lesions exhibited enhance germ cell death when exposed to cisplatin following downregulation 
of oct-1. In contrast, depletion of oct-2 by RNAi in the xpa-1 mutant animals suppressed the high level of 
apoptotic cells observed in this mutant upon exposure to cisplatin. These data indicate that upregulation of 
oct-2 burdens the xpa-1 mutant animals with cisplatin-induced DNA lesions leading to the enhancement of 
germ cell death [51] [52]. Thus, the current studies suggest that by combining defects of various DNA 
repair pathways with functional organic cation transporters such as OCT-2, it is possible to determine 
whether an unknown compound has genotoxic effects and the type of lesions it may create.  
OCT-2 transports the RAD51 inhibitor B02 
In addition to the genotoxic agents that docked onto OCT-2, the analyses revealed that many chemical 
compounds such as 3-benzyl-2-[(E)-2-pyridin-3-ylethenyl]quinazolin-4-one (B02, CID: 5738263), referred to 
as B02, has the ability to robustly interact with OCT-2, and not OCT-1. In human cells, B02 has been shown 
to interfere with the DNA strand exchange and the nuclear foci formation catalyzed by the DNA repair 
protein RAD51. RAD51 is required to repair DNA double strand breaks during meiosis and in response to 
DNA damaging agents [53-55]. Examination of the pharmacological effect of B02 in C. elegans revealed 
that this inhibitor caused sterility in the oct-1 null mutant. This is marked by the production of inviable 
embryos and a decrease in the number of viable animals, phenotypes that mimic those of the rad-51 
homozygotes [56]. As predicted from the model, downregulation of oct-2 in the oct-1 null mutant 
prevented the B02 ligand from causing sterility [33]. Under these conditions, the oct-1 null mutant 
produced viable embryos that resulted in nearly normal levels of viable animals [33]. From these data, it is 
clear that B02 can also inhibit RAD-51 function in C. elegans and this depends on the function of the OCT-2 
uptake transporter [33]. Thus, the docking scores of ligands and proper readouts from the targeted 
pathway provide valuable tools to monitor transporter-mediated drug uptake into C. elegans.  
Perspectives 
There is no evidence yet that OCT-1 can function as an uptake transporter in C. elegans, although when 
expressed in two different heterologous model system, human and yeast cells, it can stimulate uptake of 
tetraethylammonia and doxorubicin, respectively [18, 31]. While in human cells downregulation of OCT1 
caused resistance to anthracyclines, this was not the case in C. elegans devoid of OCT-1, thus a direct role 
for OCT-1 in the uptake of anthracyclines can be excluded. Whether OCT-1 acts as an uptake transporter 
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for selective drugs remains a possibility. Nonetheless, in C. elegans OCT-1 has a role in exerting control on 
oct-2 expression, and it is OCT-2 that is primarily involved in the uptake of doxorubicin and other 
substrates. We believe that OCT-2 has a broad specificity and can transport various substrates, including 
toxic environmental compounds, from the pharynx into the intestine (Fig. 1). The OCT-2 in the intestine 
then transports the substrates into the vicinity of the oocytes and embryos, which are also equipped with 
the OCT-2 transporter (Fig. 1). Thus, removal of OCT-2 stands to protect the animal from germ cell death 
induced by environmental and chemical toxicants. The data obtained so far underscore the importance of 
uptake transporters in regulating the entry of drugs into cells and raise the possibility that (i) the drug-
resistance and -sensitivity exhibited by cancer patients could be governed at the level of the uptake 
transporters and (ii) the absence of one transporter could greatly impact the function of another.  
 
Figure 1. Illustration of key features of an adult C. elegans hermaphrodite. The blue squiggly line represents 
the putative location of OCT-1 transporter, while the red squiggly line and short vertical red bar represent the 
putative locations of OCT-2 transporter on the pharynx, intestine, oocytes and embryos.  
The studies to date also raised additional concern and that is whether the upregulated OCT-2 
transporter can import compounds from the growth media that cause DNA damage and ultimately leading 
to genomic instability over time. If this were the case, then individuals with deregulated uptake 
transporters are likely at increased risk of being bombarded with genotoxic compounds that could lead to 
various diseases such as cancers. In fact, preliminary data revealed that the upregulation of OCT-2, via 
RNAi downregulation of oct-1, resulted in at least a two-fold increase in spontaneous mutations in a C. 
elegans strain designed to monitor frame shift mutations at the lacZ reporter gene [57].  
The downregulation of oct-1 leading to the upregulation of oct-2 was an unexpected finding, and 
provides a compelling argument that the animal has evolved tight regulation of OCT-2 presumably to 
control uptake of unwanted compounds. OCT-1 could perform a function as a surface sensor that acts as 
non-transporting transceptors by sensing the availability of nutrients and signaling the regulation of 
downstream plasma membrane transporters [32, 58]. Thus, when nutrients are scarce, OCT-1 might serve 
as a sensor to promote the upregulation of OCT-2 to scavenge the limited resources, but sustain basal 
expression of OCT-2 when nutrients are in surplus. This mode of regulation has been characterized in S. 
cerevisiae, Drosophila melanogaster and Homo sapiens [59-61]. Thus, in view of the increasing number of 
sensors that are currently being identified in various organisms, it is plausible that C. elegans OCT-1 may 
indeed act either as a non-transporting or transporting sensor leading to the regulation of oct-2 expression. 
If such a model is possible, other factors including kinases and transcriptional activators would be involved 
in conveying the signal from OCT-1 to promote OCT-2 expression as shown for the S. cerevisiae Ssy1 amino 
acid sensing pathway [62].  
We propose that exploiting OCT-2 in C. elegans could have far reaching applications that supersede 
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other whole model systems in drug discovery programs with respect to cost and time. Thus, maintaining 
the OCT-2 transporter at optimal levels should be a useful step to incorporate into any high-throughput 
screens to improve the efficiency of identifying cationic bioactive molecules from chemical libraries. The 
overexpressed OCT-2 is expected to significantly alter its kinetics such that it can transport chemicals that 
are present at lower concentrations in the libraries. We strongly suggest that the previous barriers posed 
by C. elegans to find bioactive molecules could be explained by the lack of an activated mechanism to 
efficiently take up compounds at lower concentrations.  
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